Neurosurgery Procedures & Complications
Hospitalists will likely be increasingly responsible for the co-management of neurosurgical patients and should be familiar with the most common neurosurgical procedures and managing potential medical complications.
II. Identify the Goal Behavior.
III. Describe a Step-by-Step approach/method to this problem.
Step 1: Determine Revised Cardiac Risk Index (RCRI) score
Step 2: Assess patient's functional exercise capacity
Spinal Decompression and Fusion
IV. Common Pitfalls.
Anticoagulation and antiplatelet therapy:
- Discuss with neurosurgeon before starting anything that could increase bleeding risk
Volume management in patients with subarachnoid hemorrhages:
- Balancing risk of vasospasm with cardiopulmonary status
- Titrating BP meds too fast
Long-term steroid use:
- GI prophylaxis, glycemic control, counseling on muscle wasting/confusion/increased bleeding risk
V. National Standards, Core Indicators and Quality Measures.
No national standards/benchmarks established yet.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed